Compare BGX & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGX | BIOA |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.0M | 175.7M |
| IPO Year | N/A | 2024 |
| Metric | BGX | BIOA |
|---|---|---|
| Price | $11.82 | $12.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 67.9K | ★ 308.1K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 10.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.69 | $2.88 |
| 52 Week High | $12.44 | $13.08 |
| Indicator | BGX | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 50.31 | 82.92 |
| Support Level | $11.76 | $8.46 |
| Resistance Level | $11.90 | $9.62 |
| Average True Range (ATR) | 0.11 | 0.72 |
| MACD | 0.01 | 0.33 |
| Stochastic Oscillator | 65.22 | 92.49 |
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.